# RAMPART (NCT03288532)

> Renal Adjuvant MultiPle Arm Randomised Trial

No report yet. It can be ordered.

- Drugs tested: durvalumab; durvalumab plus tremelimumab
- Indication: intermediate- or high-risk resected renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03288532
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University College, London
- Conditions: Renal Cell Carcinoma
- Interventions: Durvalumab; Tremelimumab
- Enrollment: 1750
- Primary outcome: Disease Free Survival (DFS): Arm C vs A
- Primary outcome: Disease Free Survival (DFS): Arm B vs A
- Primary outcome: Overall Survival (OS): Arm C vs A (high risk patients only)
- Primary outcome: Overall Survival (OS): Arm B vs A (high risk patients only)

## Indexed commentary on RAMPART so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 106
- YouTube: 41
- Podcasts: 38
- X videos: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rampart-nct03288532

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03288532", "email": "<work email>"}; the inbox owner confirms by the emailed link.